Lilly Endowment Inc's Form 4 filing
Eli Lilly & Co (LLY) · filed Jan 12, 2024
- Accession no.
- 0001415889-24-001028
- Filed
- Jan 12, 2024
- Trade date
- Jan 11, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions. Open-market sales total $7.83M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lilly Endowment IncCIK 0000316011 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,500 | $630.24F1 | −$945,360 | 99,554,654 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,200 | $631.67F2 | −$758,004 | 99,553,454 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,724 | $632.84F3 | −$1,091,016.16 | 99,551,730 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,200 | $633.91F4 | −$760,692 | 99,550,530 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −2,799 | $635.05F5 | −$1,777,504.95 | 99,547,731 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −2,721 | $635.94F6 | −$1,730,392.74 | 99,545,010 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −1,000 | $636.86F7 | −$636,860 | 99,544,010 | Direct | |
| Jan 11, 2024 | Common Stock | SSaleDisposed | −200 | $639.13F8 | −$127,826 | 99,543,810 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.00 to $630.75, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7) and (8) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.22 to $632.215, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.48 to $633.37, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $633.525 to $634.17, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $634.525 to $635.51, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $635.53 to $636.45, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $636.635 to $636.94, inclusive.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $638.96 to $639.30, inclusive.
Referenced by the price of 1 transaction in Table I.